MedTrace Logo

Irbesartan Versus Amlodipine: The OBI Study

NCT00987662 · Status: WITHDRAWN · Phase: PHASE4 · Type: INTERVENTIONAL

Last updated 2014-02-11

No results posted yet for this study

Summary

Objective:

1. To study the effectiveness of irbesartan 300mg and amlodipine 10 mg in 24h ambulatory blood pressure values in obese subjects
2. To study the drug specific effect in arterial stiffness
3. To study possible drug mechanisms in obesity (reduction of central adiposity and changing the ratio of leptin to adiponectin)

Conditions

Interventions

DRUG

Irbesartan

Treatment with irbesartan 300mg for 4 weeks. IF ABP\>135/85 mmHg add hydrochlorothiazide 12.5 mg.

DRUG

Amlodipine

Treatment with amlodipine 10 mg for 4 weeks. If ABP\>135/85 mmHg add hydrochlorothiazide 12.5 mg

Sponsors & Collaborators

  • Aristotle University Of Thessaloniki

    lead OTHER

Principal Investigators

  • Vasilios Kotsis, Prof · AUTH

Study Design

Allocation
RANDOMIZED
Purpose
DIAGNOSTIC
Masking
NONE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
60 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2012-01-31
Primary Completion
2013-01-31
Completion
2014-01-31

Countries

  • Greece

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00987662 on ClinicalTrials.gov